AMGEN Inc.
AMGN
Market Cap$142.91B
Close$
Earnings Call Q1 2025
May 1, 2025 - AI Summary
Strong Financial Performance: Amgen reported Q1 2025 revenues of $8.1 billion, a 9% year-over-year increase. Volume growth contributed 14%, with 14 products achieving double-digit sales growth. This performance indicates robust demand for their portfolio, underlining the company's operational strength despite a slight 6% decline in net selling prices.
Key Growth Drivers: Significant products such as Repatha and EVENITY delivered notable sales growth. Repatha sales rose 27% year-over-year to $656 million, while EVENITY increased 29% to $442 million. The growth in these products reflects Amgen's commitment to addressing significant medical needs, particularly in cardiovascular and bone health, creating long-term growth opportunities.
Pipeline Advancements: The company achieved several regulatory milestones, including FDA approval for UPLIZNA in IgG4-related disease and positive Phase III data for various products, affirming Amgen's strength in immunology and oncology. The pipeline progress suggests an ongoing commitment to innovation that can expand market opportunities.
Exclusive for Stockcircle Pro members
Sign up
$791.27
192.6% upside
Current Fair Value
192.6% upsideUndervalued by 192.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $142.91 Billion |
|---|---|
| Enterprise Value | $191.48 Billion |
| Dividend Yield | $9.13 (3.43517194672285%) |
| Earnings per Share | $7.56 |
| Beta | 0.5 |
| Outstanding Shares | 538,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 24.1 |
|---|---|
| PEG | -1.48 |
| Price to Sales | 4.29 |
| Price to Book Ratio | 24.59 |
| Enterprise Value to Revenue | 5.62 |
| Enterprise Value to EBIT | 25.66 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 9.24 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About AMGEN Inc.
22,000 employees
CEO: Robert Bradway Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advan...